AbbVie vs Royalty Pharma
AbbVie (ABBV) and Royalty Pharma (RPRX) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $506B
- Last close
- $286.20
- 12 months
- +24.7%
- Market value
- $39.4B
- Last close
- $68.45
- 12 months
- +78.3%
At a glance
- By market value, AbbVie ($505.9B) is about 13 times Royalty Pharma ($39.4B).
- Over the last 12 months AbbVie's share price moved +24.7% and Royalty Pharma's +78.3%; against the S&P 500 that is +19.0 points and +72.6 points.
- In their last fiscal years AbbVie kept 6.9% of revenue as net income and Royalty Pharma 32.4%.
- In the last 90 days insiders reported 0 open-market purchases at AbbVie and 0 at Royalty Pharma; members of Congress disclosed 1 trade in AbbVie and 0 in Royalty Pharma.
- Next results: AbbVie Feb 2, 2027, Royalty Pharma Feb 9, 2027.
Share prices on one chart
AbbVie and Royalty Pharma, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| AbbVie ABBVNYSE · Pharmaceuticals | Royalty Pharma RPRXNASDAQ · Pharmaceutical Preparations | |
|---|---|---|
| Size and profitability | ||
| Market value | $506B | $39.4B |
| Revenue, last fiscal year | $61.2B | $2.38B |
| Net income, last fiscal year | $4.23B | $771M |
| Net marginNet income as a share of revenue | 6.9% | 32.4% |
| Free cash flow | $17.8B | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
AbbVie against
Common questions
How is AbbVie different from Royalty Pharma?
AbbVie (ABBV) is in Pharmaceuticals on NYSE, with $61.2B of revenue in its last fiscal year and a net margin of 6.9%. Royalty Pharma (RPRX) is in Pharmaceutical Preparations on NASDAQ, with $2.38B of revenue in its last fiscal year and a net margin of 32.4%. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do AbbVie and Royalty Pharma compare in size?
AbbVie has the larger market value: AbbVie $506B and Royalty Pharma $39.4B, at the last close.
Whose share price rose more over the last 12 months, ABBV or RPRX?
Over the last 12 months AbbVie moved +24.7% and Royalty Pharma +78.3%. Past price moves say nothing about the future.
Which has had more insider buying, AbbVie or Royalty Pharma?
Since 2006, AbbVie insiders reported 25 open-market purchases against 18 for Royalty Pharma. These are counts of what was filed, not a view on either stock.
Do members of Congress trade ABBV or RPRX?
In the last 12 months, members of Congress disclosed 9 trades in AbbVie (ABBV) and 0 in Royalty Pharma (RPRX).
When did insiders last buy ABBV and RPRX?
AbbVie: Mar 30, 2020. Royalty Pharma: Jun 28, 2023.
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
AbbVie pageRoyalty Pharma pageRare insider trades this weekAll comparisons
https://oqro.io/compare/abbv-vs-rprx







